All In Biotech

Drug Trial Radar · NCT07611513

Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).

Multicenter, Randomized, Double-blind, Placebo-Controlled Phase IIIa Clinical Trial on the Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children Aged 6 to 71 Months.

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Dec 2027

Study completion Sep 2028

Sponsor

Lead sponsor
Sinovac Biotech Co., LtdIndustry
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children aged 6 to 71 months. Participants will be randomly assigned in a 1:1 ratio to the trial group and the placebo group, receiving two doses of experimental vaccine or placebo , with a one-month interval between the two doses.

Conditions

  • Hand, Foot, and Mouth Disease(HFMD)
  • Herpangina

Interventions

  • Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)Biological

    Two doses are administered with a one-month interval between each dose.

  • PlaceboBiological

    Two doses are administered with a one-month interval between each dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the protective efficacy of the investigational vaccine against HFMD caused by any serotype of EV71, CA16, CA10 and CA6 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)
  2. Evaluate the protective efficacy of the investigational vaccine against HFMD caused by CA6 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)From day 15 after the full-course vaccination to data cutoff date of primary analysis
  3. Evaluate the protective efficacy of the investigational vaccine against HFMD caused by CA16 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Provincial Center for Disease Control and Prevention

    Fujian, China

  • Henan Provincial Center for Disease Control and Prevention

    Henan, China

  • Hubei Provincial Center for Disease Control and Prevention

    Hubei, China

  • Sichuan Provincial Center for Disease Control and Prevention

    Sichuan, China

  • Anhui Provincial Center for Disease Control and Prevention

    Hefei, Anhui, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.